A Phase 1, Multi-Center, Safety, Dose Escalation, Pharmacokinetics of INV-1120 in Adult Patients Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
Phase 1, first-in-human, open-label dose-escalation study to determine the MTD and RP2D, and
to assess the DLT of INV-1120 (also referred to as investigational product or IP). The
safety, tolerability, and PK of INV-1120 will be assessed in adult patients with advanced
solid tumors.